FOUR leading experts in the field of oncology were brought together in an interview to discuss the epidemiology, treatment decisions, and emerging treatment paradigms of EGFR-mutated advanced non-small cell lung cancer (NSCLC). Recent clinical evidence was also reviewed, including the RELAY trial.
Latest articlesAll articles
Editor’s Pick: More than FOLFOX and FOLFIRI: The Management of Metastatic Colorectal Cancer in the Era of Precision Oncology
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the USA. Despite improvements in screening rates and in the overall survival (OS) of patients with localised and advanced disease over the past few decades, the 5-year OS of patients with metastatic disease is still extremely poor and estimated to be approximately 15%.
Perspectives on Hepatic Metastases and the Minimally Invasive Approach to Resection
The liver is the most common site for colorectal cancer (CRC) metastases, accounting for 80% of patients with Stage IV CRC and 40% as the only site of distant disease. Of the patients with CRC, 20–25% present with synchronous metastases and 50–60% will develop metachronous disease. Liver metastases develop in the absence of lymph node involvement and, presumably, this occurs via the haematogenous route (the portal circulation) in gastrointestinal tumours from where tumour cells can embolise via the mesenteric veins.
Evaluation of Treatment Outcome and Acute Toxicity in Patients Undergoing Adjuvant Therapy in Ductal Carcinoma Pancreas: A Prospective Observational Study
Pancreatic cancer is the eleventh most commonly diagnosed cancer worldwide and is the seventh leading cause of cancer-related death. It can arise from both exocrine (95%) and endocrine portion (5%) of the pancreatic gland. The most common histology is ductal adenocarcinoma of the pancreas, which accounts for around 80% of all pancreatic cancers, while 65% of the cases arise in the pancreatic head, 15% in the body or tail, and 20% involve the gland diffusely.